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ABSTRACT GRAPHIC
Schematic representation for preparation of the folate-decorated nanocomplexes (Fol-CDplexes) 
from paCD T2, plasmid DNA and folic acid.
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ABSTRACT 
Aim: Development and evaluation of a new targeted gene delivery system by first 
preforming self-assambled nanocomplexes from a polycationic amphiphilic 
cyclodextrin (paCD) and pDNA and then decorating the surface of the nanoparticles 
with folic acid (FA). Experimental Section:  The cyclodextrin derivative (T2) is a 
tetradecacationic structure incorporating 14 primary amino groups and 7 thioureido 
groups at the primary face of a cyclomaltoheptaose (β-CD) core and 14 hexanoyl chains 
at the secondary face. Results and Conclusions: T2 complexed and protected pDNA 
(luciferase-encoding plasmid DNA, pCMVLuc) and efficiently mediated transfection in 
vitro and in vivo with no associated toxicity. The combination of folic acid with 
CDplexes afforded ternary nanocomplexes (Fol-CDplexes) that enhanced significantly 
the transfection activity of pCMVLuc in human cervix adenocarcinoma HeLa cells, 
especially when formulated with 1 µg FA/µg DNA. The observed transfection 
enhancement was associated to specific folate receptor (FR)-mediated internalization of 
Fol-CDplexes, as corroborated by employing a receptor-deficient cell line (HepG2) and 
an excess of free folic acid. The in vivo studies, including luciferase reporter gene 
expression and biodistribution, indicated that 24 h after intravenous administration of 
the T2-pDNA nanocomplexes, transfection takes part mainly in the liver and partially in 
the lung. Interestingly, the corresponding Fol-CDplexes lead to an increase in the 
transfection activity in the lung and the liver compared to non-targeted CDplexes. 
Folate-CDplexes developed in this study have improved transfection efficiency and 
although various methods have been used for the preparation of ligand-DNA-
complexes, covalent binding is usually needed and insoluble aggregates are formed 
unless the concentration of the components are minimized. However, the complexes 
developed by first time in this work were prepared by simple mixing. The synthetic 
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nature of this formulation provides the potencial of flexibility in terms of composition, 
and the capability of inexpensive and large-scale production of the complexes. These 
nanovectors may be an adequate alternative to viral vectors for gene therapy in the 
future. 
KEYWORDS: Gene delivery, nanomedicine, pharmaceutics, polycationic amphiphilic 
cyclodextrins, folate receptors, folic acid. 
INTRODUCTION 
Gene therapy provides great strategies for treating different diseases as cancer [1], 
genetic disorders [2]  and infectious diseases [3]. Gene delivery systems should be 
developed to save genetic material from premature degradation in systemic blood 
stream and to efficiently transfer the therapeutic genes to target cells. That’s why, 
recently, research of new gene therapy vectors has been increased. In general, gene 
delivery vectors are divided into two principal groups: recombinant virus [4]  and 
synthetic vectors [5]. Viral-based delivery systems like retroviruses, adenoviruses and 
adeno-associated viruses show high transfection efficiency. However, their limited 
DNA carrying capacity, expensive cost and safety concerns such as immunogenic 
response, toxicity or oncogenicity [6], as well as the possibility of conversion of benign 
virus into wild virus, are major limitations inherent to these vectors. Compared to viral 
vectors, non-viral (synthetic) systems are attractive alternatives for improved safety, 
greater flexibility and easier manufacturing. Because of that, the design of efficient and 
biocompatible non-viral vectors has been developed. Most of the current examples 
comprise two categories, namely cationic polymers and cationic lipids. However, the 
main problem is that these types of vectors have difficulty in obtaining high levels of 
expression and high selectivity in some cell lines.  
5 
 
Cyclodextrins (CDs) are naturally occurring cyclic oligosaccharides composed of 
α(1→4)-linked glucose units arising from enzymatic degradation of starch that hold a 
privileged position as drug delivery and controlled drug release systems. Apart from 
their inherent properties as nanometric containers, CDs ability to improve drug 
bioavailability has been suggested to benefit from two additional features: (i) their 
membrane absorption enhancing properties and (ii) their ability to stabilize 
biomolecules in physiological media by shielding them from nonspecific interactions 
[7]. CDs interaction with biological membranes results in the release of certain 
membrane components (e.g. cholesterol or phospholipids) and consequently their 
destabilization and permeabilization [8]. Their unique molecular inclusion properties  is 
also an important advantage.  
Although the effectiveness of the best cyclodextrin-based gene delivery systems 
currently developed, as for other nonviral gene vectors, remains orders of magnitude 
poorer compared with viral vectors, the possibility to combine covalent and 
supramolecular approaches offers new venues for the design of tailor-made artificial 
viruses. Actually, some CD-based vector formulations have reached clinical phase 
studies [9,10], particularly in the very active field of RNA nanotechnology for the 
delivery of therapeutic nucleic acids [11-13]. The role of CDs as transfection enhancers 
in formulations containing cationic lipids, cationic polymers or even viral vectors has 
been known for a long time [14-18]. However, the real potential of CDs in gene therapy 
has only been revealed by exploiting selective chemical functionalization tools [19]. 
Noteworthy, polycationic CD-based vectors were shown to self-organize in the presence 
of pDNA to promote compaction and safe delivery to cells [20-22]. Threading CD 
polycations by linear polymeric chains affords polyrotaxanes that likewise complex 
nucleic acids into transfectious nanoparticles [23-27]. 
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Monodisperse polycationic amphiphilic cyclodextrins (paCDs) have been further shown 
to exhibit better self assembling properties in the presence of plasmid DNA (pDNA) 
and the resulting nanocomplexes (CDplexes) exhibited enhanced cell-membrane 
crossing capabilities [28,29]. 
In a previous work, a set of paCDs with various architectures was evaluated with a 
focus in cancer therapy [30]. Although some candidates exhibited promising features, 
the lack of selectivity of the resulting CDplexes between cancerous and healthy cells 
was an anticipated disadvantage. To achieve active targeting, the CDplexes should be 
equipped with functional molecules, which can recognize and adhere to the biomarkers 
on the surface of the corresponding cancer cells. 
Because folic acid (FA) is essential for the biosynthesis of nucleotide bases, the vitamin 
is consumed in elevated quantities by proliferating cells.  The attractiveness of folate 
has been further enhanced by its high binding affinity (Kd ≈10-10), low 
immunogenicity, ease of modification, small size (Mw 441,4), stability during storage, 
compatibility with a variety of organic and aqueous solvents, low cost and ready 
availability [31]. Folate receptors (FR) are frequently overexpressed on cancer cells, 
identifying the receptor as a potential target for a variety of ligand and antibody-directed 
cancer therapeutics [32,33]. These receptors are elevated in malignant tissues of the 
ovary, uterus, endometrium, brain, kidney, head and neck and skin, among others, but 
they are also present in some healthy tissues [34,35]. Folate binding to different non-
viral systems for drug and gene delivery has been studied by some authors [31,36-40].  
Targeted cyclodextrin-containing vectors equipped with lactose [41], mannose [42], 
folate [43] and transferrin ligands [44] have been studied in gene delivery. However, in 
all these formulations the cyclodextrin material had to be combined with another 
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polymer, usually PEI, to be efficient. In the absence of any helper, only the polycationic 
amphiphilic cyclodextrins synthetized in our group have shown to mediate site-specific 
gene delivery. It required the incorporation of mannosyl [45] or galactosyl [46] 
glycotopes onto the cyclodextrin scaffold through chemical ligation methods prior to 
CDplex assembly. 
Aiming at developing paCD-DNA nanocomplexes with improved tumour cell-
discriminating abilities for cancer gene therapy, we have now explored an alternative 
strategy consisting in the post-decoration of preformed CDplexes with folic acid. The β-
cyclodextrin derivative T2, having a tetradecacationic structure incorporating 14 
primary amino groups and 7 thioureido groups at the primary face of a 
cyclomaltoheptaose (β-CD) core and 14 hexanoyl chains at the secondary face, was 
chosen as the paCD prototype. T2 has been previously shown to efficiently complex 
and compact pDNA into CDplexes with positive surface potential that promoted 
transfection in several cell lines [30]. We hypothesized that these CDplexes would 
interact electrostatically with folic acid to form ternary T2:pDNA:FA nanocomplexes 
(Fol-CDplexes) in which the FA ligands would be exposed at the nanoparticle surface 
and available for molecular recognition by folate receptors at the membrane of cancer 
cells (Figure 1). The capabilities of the new system to promote FR-mediated 
transfection have been investigated in comparison with PEI formulated polyplexes. 
MATERIALS AND METHODS 
Materials 
The polycationic amphiphilic cyclodextrin T2, synthetized as previously 
reported 20, was used for CDplex formulation. Polyethylenimine 25 (bPEI, MW 25 
kDa, branched) was purchased from Aldrich. The plasmid pCMV-Luc VR1216 (6934 
8 
 
bp) encoding luciferase (Clontech, Palo Alto, CA, USA) used for transfection 
experiments was amplified in E. coli, isolated, and purified using Qiagen Plasmid Giga 
Kit (Qiagen GMBH, Hilden, Germany). Folic acid dehydrate, HEPES and D(+)-glucose 
were purchased from Sigma (Madrid, Spain). Alamar blue dye was purchased from 
Accumed International Companies (Westlake, OH, USA). 
Cell culture 
HeLa (human cervix adenocarcinoma) and HepG2 (human hepatoblastoma) 
cells were obtained from American Type Culture Collection (Rockville, MD, USA) and 
were maintained at 37 ºC under 5% CO2 in complete medium constituted by 
Dulbecco’s modified Eagle’s medium-high glucose + glutaMAX® (Gibco BRL Life 
Technologies) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 
penicillin (100 U/mL) and streptomycin (100 µg/mL). Cells were passaged by 
trypsinization twice a week. 
Preparation of plain and Fol-CDplexes 
Plain- or targeted CDplexes were prepared by mixing the plasmid pCMVLuc and the 
cyclodextrin derivative T2 at protonable nitrogen/phosphate (N/P) ratio of 5. The N/P 
ratio refers to the number of protonable nitrogens in the CD derivative per phosphates in 
DNA. Complexes were prepared in the absence (plain-CDplexes) or in the presence of a 
variable amount of the ligand folic acid (FA) (Fol-CDplexes). They contained 5 µg/mL 
of DNA and were prepared in HEPES 10 mM containing 5 % (w/v) of glucose at pH 
7.4. The preparations were orbitally stirred for 2 h prior to nano complex 
characterization or transfection experiments. Polyplexes used as control were 
formulated with bPEI (25 kDa) at N/P ratio of 5. 
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Particle size and zeta-potential measurements 
The particle size of plain- and targeted nanocomplexes was measured by 
dynamic light scattering (DLS), and the overall charge by zeta-potential measurements, 
using a particle analyzer (Zeta Nano Series, Malvern Instruments, Spain). Samples of 
the prepared complexes were diluted in distilled water and were measured at least three 
times for 2 h after preparation and incubation of the complexes. Size results are given as 
volume distribution of the major population by the mean diameter with its standard 
deviation. 
In vitro transfection activity 
 The procedure for in vitro transfection assays was the same for HeLa and HepG2 
cell lines. Cells were seeded in medium (100.000 cells/well) in 48-well plates (Iwaki 
Microplate, Japan), and incubated for 24 h at 37 ºC in 5% CO2. After this, the medium 
was removed and 0.3 mL of complete medium (with 10% serum) and 0.2 mL of 
complexes (containing 1 µg of pDNA) were added to each well. After 4 h incubation 
the medium was replaced by complete medium and the cells were further incubated for 
48 h. Cells were washed with phosphate-buffered saline (PBS) and lysed with 100 µL of 
Reporter Lysis Buffer (Promega, Madison, WI, USA) at room temperature for 10 min, 
followed by a freeze-thaw cycle. 20 µL of the supernatant was assayed for total 
luciferase activity using the luciferase assay reagent (Promega), according to the 
manufacturer’s protocol. A luminometer (Sirius-2, Berthold Detection Systems, 
Innogenetics, Diagnóstica y Terapéutica, Barcelona, Spain) was used to measure 
luciferase activity. The protein content of the lysates was measured by de DC protein 
Assay Reagent (Bio-Rad, Hercules, CA, USA) using bovine serum albumin as the 
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standard. The data were expressed as nanograms of luciferase (based on a standard 
curve for luciferase activity) per milligram of protein. 
Cell viability 
 Cell viability was quantified by a modified Alamar Blue Assay. Briefly, 2 ml of 
10% (v/v) Alamar blue dye in DME-HG supplemented with 10% (v/v) FBS medium 
were added to each well 48 h post-transfection. After 2.5 h of incubation at 37 ºC, 200 
l of the supernatant was assayed by measuring the absorbance at 570 and 600 nm. Cell 
viability, expressed as a percentage of control cells, was calculated according to the 
formula (A570 - A600) of treated cells X 100/ (A570 - A600) of control cells. 
In vivo transfection studies 
Female Balb-c mice (6-8 weeks of age, 20-25 grams weigh) were purchased 
from Harlan Ibérica Laboratories. All animals were studied in accordance with 
guidelines established by Directive 86/609/EEC and with the approval of the Committee 
on Animal Research at the University of  Navarra (Pamplona, 033/00). Individual mice 
in groups of six were injected via the tail vein with 200 µL of Fol-CDplexes containing 
60 µg of pCMV-Luc and prepared at N/P 5. Naked DNA was injected as control. 
Twenty four hours after injection the mice were sacrificed. The liver, heart, lungs and 
spleen were collected and washed with cold PBS. The organs were homogenized with 1 
mL lysis buffer using an homogenizer at 5000 rpm (Mini-Beadbeater; BioSpec 
Products, Inc., Bartlesville, OK, USA) and centrifuged at 10000 rpm for 3 min. 20 µL 
of the supernatant were analysed for luciferase activity following the same procedure as 
for in vitro assays. For in vivo imaging over time, the plasmid pCMV-Luc and D-
Luciferin (Promega, Mannhein, Germany) were used. Images were taken with an IVIS 
CCD camera system (Xenogen) and analyzed with the Living Image 2.6 software 
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package (Xenogen). Mice were anesthetized with a mixture of Xylacine and Ketamine 
(at a dose of 8 mg/kg and 60 mg/kg, respectively) and 150 mg/kg of D-luciferin were 
injected intraperitoneally. Ten minutes later, animals were placed in the dark chamber 
for light acquisition.  
 
Statistical Analysis 
Results are reported as the mean values ± standard deviation. Statistical analysis 
was performed with SPSS 15.0 (SPSS®, Chicago, IL, USA). The different formulations 
were compared with ANOVA (Tukey post-hoc adjust). Differences were considered 
statistically significant at p<0.05. 
 
RESULTS 
Characterization of CDplexes 
The relevance of the size and surface charge in gene delivery by non-viral vectors is 
known. A small particle size is specially required for in vivo gene delivery in order to 
allow systemic delivery. 
Plain- and Fol-CDplexes prepared at a DNA concentration of 5 µg/mL and containing 
different amounts of folic acid ligand were characterized in terms of size and surface 
charge prior to in vitro transfection assays. Table 1 shows the values of the particle size 
and the zeta-potential of complexes at N/P ratio of 5, in the absence or presence of 
increasing amounts of folic acid. The size and the overall charge of plain CDplexes 
were 254 nm and 34 mV, respectively. No significant differences were observed in the 
size of complexes when the amount of folic acid was 2 µg or lower. Complexes were 
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stable and the polydispersity index was lower than 0.3 in all cases. CDplexes formulated 
with 5 µg FA/µg DNA aggregated significantly. The zeta-potential of CDplexes showed 
clearly positive values. By increasing the amount of the ligand, lower values of zeta-
potential were obtained, as expected, given that folic acid is negatively charged.  
   
In vitro transfection activity by Fol-CDplexes 
Transfection experiments in HeLa and HepG2 cells were carried out in the 
presence of 10% (v/v) FBS. Polyplexes prepared with bPEI were used as control. Plain 
(non-targeted) and Fol-CDplexes were prepared at N/P 5 and contained 1µg of 
pCMVLuc and different amounts of folic acid.  
 Figure 2 shows that Fol-CDplexes formulated with 0.5 and 1 µg of folic acid 
significantly enhanced transfection activity in HeLa cells, compared to the non-targeted 
CDplexes and to the control polyplexes prepared with bPEI (p<0.001, p<0.001, p<0.01 
respectively). Nanocomplexes containing higher amounts of the ligand (2 µg) were 
slightly more effective in transfecting HeLa cells than non-targeted CDplexes. 
Transfection activity was maximal by Fol-CDplexes containing 1 µg FA/µg DNA, 
reaching a 1.7-fold higher efficiency as compared with plain-CDplexes (p<0.001).  
Specificity of targeting to the folate receptor 
In order to investigate whether or not the uptake of Fol-CDplexes is mediated via 
specific interaction with the folate receptor, additional experiments were performed 
using the FR(-) HepG2 cell line and adding an excess of free folic acid previous to the 
addition of folate-complexes. In HepG2 cells, the addition of the FA ligand decreased 
transfection performance, in agreement with the lack of folate receptors at their surface 
(Figure 3A). On the other hand, by blocking the receptors with an excess (5 mg/mL) of 
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folic acid a decrease in the transfection levels is observed by Fol-CDplexes (Figure 3B). 
No transfection activity was observed by naked DNA in HeLa or HepG2 cells. 
Cell viability 
This assay was done in order to evaluate whether plain- and Fol-CDplexes 
formulated with different amounts of folic acid were toxic to HeLa or HepG2 cells. The 
Alamar Blue Assay showed good cell viability, higher than 80% in all transfected wells, 
independently of the amount of the ligand and the cell line used. Plain- and Fol-
CDplexes turned to be less toxic compared to polyplexes prepared with bPEI (Figure 4). 
In vivo transfection activity 
In order to know if Fol-CDplexes could be used for in vivo gene delivery, complexes 
were injected systemically into mice and their activity was compared with control and 
naked DNA. Figure 5 shows the results of transfection activity in different organs by 
injecting intravenously plain- and Fol-CDplexes. By increasing the amount of the FA 
ligand, an increase in gene expression was observed in the lung and the liver compared 
to plain CDplexes. Maximal transfection activity is observed in the liver. In this organ, 
gene expression by CDplexes containing 1µg FA/µg DNA was 2 times higher as 
compared with  results obtained using plain-CDplexes. In the lung, a 4.6-fold increase is 
observed with Fol-CDplexes (1 µg FA/µg DNA) compared to nontargeted complexes. 
No transfection activity was detected in mice injected with naked DNA or control PBS. 
 
In vivo biodistribution studies 
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High gene expression levels by CDplexes containing 0.5 and 1 µg FA/µg DNA are 
observed in the liver compared to control mice injected with PBS or naked DNA, where 
no bioluminiscence is detected in any organ (Figure 6). 
 
DISCUSSION 
A crucial limiting factor in gene therapy is the low efficiency of gene transfer with the 
currently available vectors, especially in vivo. Lack of cell discriminating capabilities is 
another important limitation that becomes particularly relevant in cancer-directed 
therapies. In an attempt to solve these problems, we have engineered targeted self-
assembled nanocomplexes intended to deliver genetic material into cancerous cells. For 
that purpose, we examined the association of folic acid with CDplexes formulated with 
the C7-symmetric βCD derivative T2, which has been selected for this study on the 
basis of previous results on pDNA complexing abilities and transfection capabilities 
[30,47,48]. The polyamino-thioureido amphiphilic CD derivative T2 is readily 
accessible from commercial βCD after installation of the cysteaminyl spacer at the 
primary positions and multiple amine-isothiocyanate coupling as previously reported. 
This paCD, presenting a dendritic display of the cationic elements (Figure 1), has been 
shown to form stable complexes with pDNA (CDplexes), where the genetic material is 
fully protected from the environment that exhibit positive surface potential. We 
envisioned that electrostatic interactions with folic acid could be exploited to build 
ternary FA-T2-pDNA nanocomplexes without the need of further synthetic efforts. 
The folate receptor is highly over-expressed in a variety of carcinomas and has also 
expression in normal tissues [35]. Actually, gene delivery via folate receptor-mediated 
endocytosis has been shown to be a powerful method for the specific delivery of genes 
FIGURE 5 
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to certain cell types of tissues [37,49]. Nevertheless, one of the major limitations of 
folate-targeted gene therapy lies in the low rate of vector escape from intracellular 
compartments following folate receptor-mediated endocytosis. Since T2-formulated 
CDplexes have shown good cell internalization and endosome escaping abilities, 
assaying folate-decorated versions seemed very appealing. Additional favourable 
features are expected in view of the membrane absorption enhancing properties of CDs 
and their ability to stabilize biomolecules in physiological media by shielding them 
from non-specific interactions. CDs have also proven to be beneficial for increasing the 
stability of oligonucleotides against endonucleases or even modulating undesirable side 
effects such as immune stimulation [50]. 
The size of the complexes is a crucial parameter for efficient transfection of genes. The 
nanocomplexes developed in this work, formulated with 1-to-5 µg Fol/µg pDNA, were 
found to have nanometric size, with the exception of Fol-CDplexes containing 5 µg 
Fol/µg DNA, where aggregation is detected. For this formulation, the lowest value of 
the series in the zeta-potential is observed, which probably contribute to this result. In 
the range 0-1 µg an increase in the amount of folic acid resulted in no significant 
increase in the particle size of the targeted complexes. The small size of folic acid can 
contribute to this fact, making it an ideal ligand for targeted delivery (Table 1). 
Comparing to classical liposome systems, no extrusion process is needed to homogenize 
the particles. On the other hand, zeta-potential measurements showed that high 
concentrations of folic acid in the CDplexes are associated with a decrease in the overall 
charge of the Fol-CDplexes. This is due to the presence of two (α and γ) carboxyl 
groups in the molecular structure of the ligand. In any case, the targeted Fol-CDplexes 
evaluated in this work (containing 0.5, 1, 2 or 5 µg Fol/µg DNA) had a net positive 
zeta-potential, which may facilitate the interaction with the negatively charged outer 
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face of the cells. Nevertheless, previous work has demonstrated that cell internalization 
through specific membrane receptors can favourably compete with unspecific 
mechanisms for CDplexes bearing functional elements provided that they are 
formulated at N/P 5 [45]. 
Transfection data for targeted Fol-CDplexes formulated with T2 and 0.5 or 1 µg of FA 
per µg of DNA and the luciferase-encoding reporter gene (pCMV-Luc VR1216) at N/P 
5 in HeLa cells (FR+), compared with plain (non-targeted) CDplexes and bPEI derived 
polyplexes, indicated a noteworthy increase in efficiency (Figure 2). Some authors have 
compared non-targeted cationic cyclodextrins (CDs) as gene delivery vectors for 
transfection to standard transfection agents (Lipofectamine or Superfect), concluding 
that polycationic CDs showed higher transfection efficiencies [20,51]. Further 
decoration with folic acid appears to facilitate the internalization of the ternary 
nanocomplex due to the ability of the ligand to stimulate endocytosis. It is also 
interesting to note that Fol-CDplexes promoted efficient transfection even in the 
presence of 10% serum. At this respect, it is known that negatively charged compounds 
present in serum often inhibited transfection activity [52] and represent a serious 
limitation for the use of nonviral vectors in vivo. 
The enhancement in gene delivery by using CDplexes could be due, in part, to the 
membrane disturbing and macromolecule shielding effect of CDs. The stabilizing effect 
that CDs impart to gene delivery systems is also an important factor. Also, the cell 
membrane-disturbing effect of CDs can play a role, due to their capability to extract 
membrane components without lysing the cell, thereby making it more permeable to 
DNA, as put forward in a report by Aachmann and Aune describing successful gene 
delivery into bacteria [53]. In any case the similar particle size of plain CDplexes and 
Fol-CDplexes obtained by adding 0.5 or 1 µg of folic acid to the CDplexes indicates 
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that the increase in transfection levels obtained in HeLa cells cannot be ascribed to an 
increase in the particle size of the nano complexes. 
Another important aspect for in vivo applications studied in this work is the toxicity of 
the CDplexes. It is known that polycationic macromolecules in general may cause 
destabilization of the cell membrane leading to cell lysis, although the exact mechanism 
of this process has not yet been fully revealed. Taking this into account, cell viability 
following transfection was assessed to evaluate whether CDplexes formulated with folic 
acid at N/P 5 were toxic to HeLa and HepG2 cells. No toxicity was observed for either 
plain or Fol-CDplexes, in contrast to that observed for bPEI polyplexes, which 
represents an important advantage for the new systems. The viability values were very 
similar in all cases, indicating that the differences in transfection activity between these 
sets of complexes are not due to different toxicities of the formulations (Figure 4). 
The specificity of FR-mediated gene transfer by Fol-CDplexes was illustrated by using 
the cell line HepG2 (FR -) and an excess of free folic acid previous to addition of Fol-
CDplexes in order to block the folate receptors. In HepG2 cells, a decrease in 
transfection activity is observed by Fol-CDplexes, as compared to non-targeted ones 
(Figure 3A). Differences in transfection in groups “0.5 µg folic acid/ µg DNA” and “1 
µg folic acid /µg DNA” could be due to the bigger size and lower zeta potential of 
complexes formulated with 1 µg of folic acid, which lead to smaller values in 
transfection efficiency. In the case of blocking the folate receptors a decrease by Fol-
CDplexes is observed (Figure 3B).These results support the hypothesis that the targeted 
CDplexes are recognized by folic acid receptors on the cell surface, which in turn 
facilitates receptor-mediated endocytosis. Our observations are also in accordance with 
previous evidence showing that folate conjugates are taken up non-destructively by 
mammalian cells via receptor-mediated endocytosis [39]. 
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The extent of nanoparticle uptake in vivo is variable and also dependent on the size, 
charge, rigidity and other physicochemical properties of the particles. The in vivo 
studies based on luciferase reporter gene expression indicated that 24 h after intravenous 
administration of the paCD-based nanocomplexes transfection occurs mainly in the 
liver and only partially in the lung (Figure 5), which is in accordance with our previous 
data [30]. We think that, due to the small size of the particles, the capture by 
macrophages and Kupffer cells is avoided, so that the liver cells which are mainly 
transfected are hepatocytes. The presence of folic acid in the CDplexes lead to an 
increase in the transfection efficiency. Maybe, FR-independent processes may also 
contribute to this effect, e,g, the easier intracellular dissociation of the ternary FA-T2-
pDNA nanocomplex in the cytoplasm, the protective effect of folate around the 
complex in Fol-CDplexes or a more efficient CD-membrane permeation enhancement 
in the lung and liver tissues. Results from the biodistribution studies showed in Figure 
6, further evidenced the marked tropism of the nanocomplexes formulated with the 
paCD T2 to the liver. 
 
CONCLUSIONS 
In this work we have prepared self-assembled targeted transfectious nanocomplexes 
using a hierarchical strategy consisting in (i) complexation and compaction of the 
plasmid pCMVLuc with the polycationic amphiphilic cyclodextrin T2 and (ii) surface 
decoration of the preformed CDplexes with folic acid through supramolecular 
electrostatic interactions. Similarly to T2-pDNA CDplexes, the ternary FA-T2-
pCMVLuc nanocomplexes (Fol-CDplexes) are efficient gene vectors for gene therapy 
purposes. Fol-CDplexes efficiently protected pDNA by forming monodisperse and 
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stable nanoparticles that efficiently promoted transfection in HeLa cells, with no 
associated toxicity. The new Fol-CDplexes were also efficient vectors for gene delivery 
in vivo in a mouse model, leading to relatively high transfection levels in the lung and, 
especially, in the liver. Interestigly, the presence of the FA ligand translates into 
enhanced transfection efficiency.  All these features, together with the easy and 
relatively low synthesic cost of the appropriate derivatives, facile purification, 
robustness and stability, biocompatibility, lack of immunogenicity and safety, make the 
presented Fol-CDplexes optimal candidates for gene delivery and an adequate 
alternative to viral vectors in the future. 
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Table 1. Influence of the amount of the ligand on the particle size and zeta potential of 
CDplexes. Complexes were prepared at N/P 5 with 5 g/mL of pCMVLuc. Results are 
expressed as the mean ± s.d. of three independent experiments. 
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1 263 ± 12 14 ± 1 
2 308 ± 15 12 ± 1 
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Figure 1. Schematic representation for preparation of the folate-decorated nanocomplexes (Fol-CDplexes)
from paCD T2, plasmid DNA and folic acid (FA).
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Figure 2. Transfection of HeLa cells with plain- and Fol-CDplexes prepared at N/P 5 
containing 1 µg of DNA. PEI25-pCMVLuc polyplexes were used as control (PP25). 
The data represent the mean ± s.d. of three wells and are representative of three 
independent experiments. 
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Figure 3. Transfection of HepG2 (FR-)(A) and HeLa cells in the presence of an excess 
of folic acid (B) with plain- and Fol-CDplexes prepared at N/P 5 containing 1 µg of 
DNA. PEI25-pCMVLuc polyplexes were used as control (PP25). The data represent the 
mean ± s.d. of three wells and are representative of three independent experiments. 
Figure 3
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Figure 4. Cell viability. Effect of  plain- and Fol-CDplexes on the viability of HeLa (A) 
and HepG2 (B) cells. PEI25-pCMVLuc polyplexes were used as control (PP25). The 
dose of the gene carrier per well was 1 µg of plasmid DNA.The data represent the mean 
± s.d. of three wells and are representative of three independent experiments. 
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Figure 5. In vivo gene expression of plain- and folate-CDplexes containing 0, 0.5 and 1 
µg FA/µg DNA and 60 µg of CMVLuc. Bars represent the mean ± s.d.(n= 6 animals). 
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FIGURE 6
Figure 6. Luciferase imaging of Balb-c mice 24 h after intravenous injection of phosphate buffered saline/naked DNA (A) 
and folate-CDplexes containing 0.5 µg FA/µg DNA (B) or 1 µg FA/µg DNA (C).
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Figure 6. Luciferase imaging of Balb-c mice 24 h after intravenous injection of 
phosphate buffered saline/naked DNA (A) and folate-CDplexes containing 0.5 µg 
FA/µg DNA (B) or 1 µg FA/µg DNA (C). 
 
 
 
